aTyr Pharma Targets June for Phase 3 Filing as Efzofitimod Pipeline Accelerates

aTyr Pharma has laid out a pair of critical milestones for mid-2026 centered on its lead asset, Efzofitimod. The biotech company plans to submit an application in June to launch a global Phase 3 study of the drug in pulmonary sarcoidosis. That regulatory filing, designated study C-006, is expected to enroll approximately 372 patients and will use lung function as the primary efficacy endpoint, following guidance from the FDA.

Alongside that push toward late-stage development, the company is also wrapping up recruitment for a mid-stage trial in another fibrotic disease. The Phase 2 EFZO-CONNECT study, which is evaluating Efzofitimod in systemic sclerosis, should finish patient enrollment by the end of the first half of 2026. Management has already held a meeting with the FDA to clarify the development pathway for that indication.

The clinical engine is being funded by a cash pile that stood at roughly $68.3 million at the close of March 2026, down from over $80 million earlier in the year. That pool includes cash and short-term investments, and aTyr expects it to underwrite the transition into the next phase for pulmonary sarcoidosis as well as ongoing work on the early-stage side. Last year alone, research and development spending totaled $60.2 million, with the bulk directed toward the EFZO-FIT and EFZO-CONNECT programs.

Should investors sell immediately? Or is it worth buying aTyr Pharma?

To keep institutional investors engaged, CEO Sanjay S. Shukla and his team will appear at two investor conferences over the coming weeks, hosted by RBC and Jefferies. The appearances are timed to explain the company's strategy following the recent regulatory interactions and to highlight the commercial potential of its technology platform.

aTyr also moved recently to align management incentives with long-term shareholder value. Two directors were granted stock options covering 50,000 shares each, with an exercise price of $0.95 per share.

The June submission now stands as the clearest near-term catalyst. Investors will also watch for word by the end of that month on whether the EFZO-CONNECT recruitment target was hit on schedule.

Ad

aTyr Pharma Stock: New Analysis - 15 May

Fresh aTyr Pharma information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated aTyr Pharma analysis...

en | US0021202025 | PHARMA | boerse | 69337899 |